In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Stablon;Coaxil;Tatinol Drug Master File in Korea (Stablon;Coaxil;Tatinol KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Stablon;Coaxil;Tatinol. The MFDS reviews the Stablon;Coaxil;Tatinol KDMF as part of the drug registration process and uses the information provided in the Stablon;Coaxil;Tatinol KDMF to evaluate the safety and efficacy of the drug.
After submitting a Stablon;Coaxil;Tatinol KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Stablon;Coaxil;Tatinol API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Stablon;Coaxil;Tatinol suppliers with KDMF on PharmaCompass.